Jetrea Purple Book BLA 125422

BLA number
125422
Proprietary names
Jetrea
Proper names
ocriplasmin
Applicant
ThromboGenics Inc.
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Jetreaocriplasmin351(a)0.375MG/0.3ML (1.25MG/ML)InjectionIntravitrealSingle-Dose VialDiscVoluntarily Revoked2017-02-22
002Jetreaocriplasmin351(a)0.5MG/0.2ML (2.5MG/ML)InjectionIntravitrealSingle-Dose VialDiscVoluntarily Revoked2012-10-17

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2021-08-01U001Jetrea351(a)DiscThromboGenics Inc.
2021-08-01U002Jetrea351(a)DiscThromboGenics Inc.
2020-08-01U001Jetrea351(a)DiscThromboGenics Inc.
2020-05-01R001Jetrea351(a)DiscThromboGenics Inc.
2020-05-01R002Jetrea351(a)RxThromboGenics Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2021-08-01001Jetrea351(a)DiscVoluntarily Revoked2017-02-22
2021-08-01002Jetrea351(a)DiscVoluntarily Revoked2012-10-17
2020-08-01001Jetrea351(a)DiscLicensed2017-02-22
2020-08-01002Jetrea351(a)DiscLicensed2012-10-17
2020-05-01001Jetrea351(a)DiscLicensed2012-10-17
2020-05-01002Jetrea351(a)RxLicensed2017-02-22